Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
| Revenue (Most Recent Fiscal Year) | $91.37M |
| Net Income (Most Recent Fiscal Year) | $-147.03M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.09 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -175.64% |
| Net Margin (Trailing 12 Months) | -160.91% |
| Return on Equity (Trailing 12 Months) | -24.84% |
| Return on Assets (Trailing 12 Months) | -20.24% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $10.46 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.76 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 53.72M |
| Free Float | 38.57M |
| Market Capitalization | $1.10B |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 0.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |